These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24372322)

  • 41. Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision.
    Guo T; Wang Y; Shapiro N; Fineberg S
    Clin Breast Cancer; 2018 Aug; 18(4):e449-e454. PubMed ID: 29102711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ.
    Shin SJ; Lal A; De Vries S; Suzuki J; Roy R; Hwang ES; Schnitt SJ; Waldman FM; Chen YY
    Hum Pathol; 2013 Oct; 44(10):1998-2009. PubMed ID: 23809857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
    Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
    Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
    Radhi JM
    Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
    Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ?
    Chaudhary LN; Jawa Z; Hanif A; Szabo A; Kamaraju S; Cheng YC; Chitambar CR
    WMJ; 2018 Jun; 117(2):62-67. PubMed ID: 30048574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
    Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
    Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
    Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center.
    Shamir ER; Chen YY; Chu T; Pekmezci M; Rabban JT; Krings G
    Am J Surg Pathol; 2019 Mar; 43(3):399-408. PubMed ID: 30489319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
    Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating agreement, histological features, and relevance of separating pleomorphic and florid lobular carcinoma in situ subtypes.
    Singh K; Paquette C; Kalife ET; Wang Y; Mangray S; Quddus MR; Steinhoff MM
    Hum Pathol; 2018 Aug; 78():163-170. PubMed ID: 29753007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reliability of receptor assessment on core needle biopsy in breast cancer patients.
    Seferina SC; Nap M; van den Berkmortel F; Wals J; Voogd AC; Tjan-Heijnen VC
    Tumour Biol; 2013 Apr; 34(2):987-94. PubMed ID: 23269610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
    Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA
    Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
    L H Weischenfeldt K; Kirkegaard T; Rasmussen BB; Giobbie-Hurder A; Jensen MB; Ejlertsen B; Lykkesfeldt AE
    Acta Oncol; 2017 Sep; 56(9):1161-1167. PubMed ID: 28488912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
    J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.